ExtraSuperTadarise is a combination preparation, with its main ingredients including Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE).
How Effective Is ExtraSuperTadarise in Treatment?
Efficacy in Treating Erectile Dysfunction
Tadalafil, a component of ExtraSuperTadarise, is a long-acting PDE5 inhibitor that can significantly improve erectile function.
Clinical studies have shown that under sexual stimulation, this medication can increase blood flow to the penis, helping to achieve and maintain sufficient erectile rigidity.
It has a relatively long duration of action, providing a more flexible time window for sexual activity.
Efficacy in Treating Premature Ejaculation
Dapoxetine, another component, is a selective serotonin reuptake inhibitor (SSRI) that can prolong the ejaculatory latency period.
Clinical observations have demonstrated that this medication helps control ejaculation time, alleviate PE symptoms, and improve the quality of sexual life.
The two components work synergistically to comprehensively improve male sexual dysfunction.
Comprehensive Therapeutic Efficacy
Through its dual effects, ExtraSuperTadarise not only addresses erectile issues but also prolongs intercourse time, providing a comprehensive solution for patients with both ED and PE.
Its therapeutic efficacy has been verified in clinical practice, significantly improving patients’ sexual satisfaction and quality of life.
Eligible and Contraindicated Populations for ExtraSuperTadarise
Characteristics of Target Patients
Adult males aged 18 years and above.
Patients with both erectile dysfunction and premature ejaculation.
Patients who have poor responses to single-component treatment and require combined therapy.
Contraindicated Populations
Patients currently using any form of nitrate medications.
Patients with severe cardiovascular diseases or unstable angina pectoris.
Patients allergic to Tadalafil or Dapoxetine.
Patients with severe hepatic impairment.
Medication Monitoring for ExtraSuperTadarise
Pre-Treatment Evaluation
Comprehensive cardiovascular system assessment.
Hepatic and renal function tests.
Detailed medication history review to avoid potential drug interactions.
Evaluation of erectile function and ejaculatory control ability.
Key Monitoring Items During Treatment
Cardiovascular monitoring: Pay attention to changes in blood pressure and cardiac symptoms.
Hepatic function monitoring: Regularly check liver enzyme indicators.
Central nervous system monitoring: Monitor adverse reactions such as dizziness and drowsiness.
Visual monitoring: Watch for abnormal color vision or changes in visual acuity.
Mental status monitoring: Assess emotional changes and depressive symptoms.
Special Monitoring Requirements
Closely observe for adverse reactions after the first dose.
Monitor drug concentrations when used concomitantly with CYP3A4 inhibitors.
Regularly evaluate efficacy for long-term users.
Seek immediate medical attention if priapism (abnormal persistent erection) lasts for more than 4 hours.
